Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.
نویسندگان
چکیده
The aim of the present study was to investigate the efficacy of infliximab for the treatment of extrapulmonary sarcoidosis. A prospective, randomised, double-blind, placebo-controlled trial was conducted, with infliximab at 3 and 5 mg x kg(-1) body weight administered over 24 weeks. Extrapulmonary organ severity was determined by a novel severity tool (extrapulmonary physician organ severity tool; ePOST) with an adjustment for the number of organs involved (ePOSTadj). In total, 138 patients enrolled in the trial of infliximab versus placebo for the treatment of chronic corticosteroid-dependent pulmonary sarcoidosis. The baseline severity of extrapulmonary organ involvement, as measured by ePOST, was similar across treatment groups. After 24 weeks of drug-therapy study, the change from baseline to week 24 in ePOST was greater for the combined infliximab group compared with the placebo group. After adjustment for the number of extrapulmonary organs involved, the improvement in ePOSTadj observed in the combined infliximab group was also greater than that observed in placebo-treated patients, after 24 weeks of therapy. The improvements in ePOST and ePOSTadj were not maintained during a subsequent 24-week washout period. Infliximab may be beneficial compared with placebo in the treatment of extrapulmonary sarcoidosis in patients already receiving corticosteroids, as assessed by the severity tool described in the present study.
منابع مشابه
Update on bioagent therapy in sarcoidosis
Corticosteroids are still the cornerstone of treatment for patients with sarcoidosis requiring systemic therapy. However, alternative agents and especially methotrexate may be considered for patients with refractory disease or requiring prolonged treatment with intolerable side effects. Although bioagent therapies have hitherto not clearly demonstrated superior efficacy and safety over corticos...
متن کاملLong-term treatment with infliximab in patients with sarcoidosis.
BACKGROUND Long-term benefit and safety of infliximab treatment in patients with chronic sarcoidosis remain unclear. OBJECTIVES It was the aim of this study to assess the clinical benefit and safety of long-term infliximab treatment in patients with chronic steroid-resistant sarcoidosis. METHODS We conducted a retrospective chart review of all patients with chronic steroid-resistant sarcoid...
متن کاملInfliximab in extrapulmonary sarcoidosis: tantalising but inconclusive.
I t is a truth universally acknowledged that a new therapy with exciting prospects must be in want of placebocontrolled evaluation. In this issue of the European Respiratory Journal, JUDSON et al. [1] report that in a study of patients with sarcoidosis, the combined group with one of two infliximab regimens had a statistically significant reduction in the degree of extrapulmonary organ involvem...
متن کاملEarlobe sarcoidosis.
BACKGROUND Infliximab, a TNF-alpha blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by 18F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement. DESIGN Case-report. RESULTS AND CONCLUSIONS A patient with severe earlobe sarcoidosis, treated with infliximab, is pr...
متن کاملBeneficial effect of infliximab on refractory sarcoidosis.
INTRODUCTION Sarcoidosis is a systemic granulomatous disease. Evidence suggests that tumour necrosis factor-alpha (TNF-α) is important in the pathophysiology, and TNF-α-inhibitors such as infliximab are therefore used against sarcoidosis refractory to traditional therapies or where side effects to these are intolerable. The aim of this retrospect-ive study was to investigate the effect of infli...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The European respiratory journal
دوره 31 6 شماره
صفحات -
تاریخ انتشار 2008